Article info
PDFEditorial commentary
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the ‘old’ therapies?
- Correspondence to Prof Dr F Heidenreich, Department of Neurology and Clinical Neurophysiology, Diakoniekrankenhaus Henriettenstiftung gGmbH, Hannover 30171, Germany; fedor.heidenreich{at}ddh-gruppe.de
Citation
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the ‘old’ therapies?
Publication history
- Received April 21, 2015
- Accepted May 25, 2015
- First published September 16, 2015.
Online issue publication
April 11, 2019
Article Versions
- Previous version (11 April 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions